Stacked values of the Z-Scores of the 5-protein signature introduced by Gómez Ravetti and Moscato [<b>3</b>].

<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0017481#pone-0017481-g001" target="_blank">Figures 1A–B</a> present the stacked values of the Z-Scores of samples in the training and independent test set respectively. The 5-protein signature includes the relative abundances of IL-1 (interleukin 1 ), IL-3 (Interleukin 3 (colony-stimulating factor, multiple)), EGF (epidermal growth factor (-urogastrone)), TNF- (Tumour Necrosis Factor ) and G-CSF (colony stimulating factor 3 (granulocyte)) on a panel of 120 proteins used as reference set. Both <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0017481#pone-0017481-g001" target="_blank">Figures 1A–B</a> shows that the stacked values of the Z-Scores of this panel of five proteins are lower in those patients that will develop clinical symptoms of AD in two to five years. The figures have samples as ordered in the original publication by Ray et al. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0017481#pone.0017481-Ray1" target="_blank">[1]</a>. In <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0017481#pone-0017481-g001" target="_blank">Figure 1A</a> the leftmost 44 values correspond to those samples labelled ‘AD’, and in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0017481#pone-0017481-g001" target="_blank">Figure 1B</a> the leftmost 42 are labelled in the same way. The samples marked in red developed AD while the ones marked in blue are ‘Non-AD’ samples (Non-Demented Controls plus Other Dementias). Since a Z-Score transformation was performed on the dataset, the measured values of each protein are, in fact, relative to the variation of the other 119.